Home › Ovarian Epithelial Carcinoma › Pennsylvania
Ovarian Epithelial Carcinoma clinical trials in Pennsylvania
10 studies for Ovarian Epithelial Carcinoma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- St. Lukes University Health Network, Bethlehem
- Ann B Barshinger Cancer Institute, Lancaster
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 28, 2026 · NCT06819007A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- St. Lukes University Hospital /ID# 274362, Bethlehem
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612, Philadelphia
- West Penn Hospital /ID# 276028, Pittsburgh
RecruitingPhase 2
Ages 18 and older · Women · Updated Oct 20, 2026 · NCT06890338Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Research Site, Philadelphia
- Research Site, Willow Grove
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 16, 2026 · NCT07816666Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT04429542Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Pennsylvania, Philadelphia
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, York
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 21, 2026 · NCT07218809A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · Women · Updated Feb 3, 2026 · NCT06469281CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Alliance Cancer Specialists, PC, Doylestown
- University of Pennsylvania, Philadelphia
RecruitingPhase 2
Ages 18 and older · Women · Updated Dec 23, 2025 · NCT06690775From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.